Palatin Technologies 주식 가격. PTN - 주식 시세, 차트, 과거 거래, 주식 채팅, 재무.

포트폴리오 강화: 실시간 토론 및 실행 가능한 거래 아이디어.

프리미엄

가격

0.95

매수가

매도가

거래량

45,890

0.92 일간 변동폭 0.9669

0.68 52주 범위 5.65

market_cap

18.571M

전일 종가

0.9142

개장가

0.92

최근 거래 시간

0.95

마지막 거래 시간

01:07:59

재정 규모

US$ 43,381

VWAP

0.945324

평균 볼륨(3m)

285,123

발행 주식

19,548,167

배당수익률

주가수익률

-0.62

주당순이익(EPS)

-1.52

매출

4.49M

순이익

-29.74M

Palatin Technologies Inc is a part of the healthcare sector. The company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with unmet medical needs and commercial potential. Its programs are based on molecules that modulate the activity of the me... Palatin Technologies Inc is a part of the healthcare sector. The company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with unmet medical needs and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its main product in clinical development is bremelanotide, which treats hypoactive sexual desire disorder, which is a type of female sexual dysfunction. 더 보기

섹터

Pharmaceutical Preparations

산업

Pharmaceutical Preparations

웹사이트

palatin.com

본부

Wilmington, Delaware, USA

설립됨

Palatin Technologies Inc New is listed in the Pharmaceutical Preparations sector of the 아메리카 증권거래소 with ticker PTN. The last closing price for Palatin Technologies was US$0.91. Over the last year, Palatin Technologies shares have traded in a share price range of US$ 0.68 to US$ 5.65.

Palatin Technologies currently has 19,548,167 shares in issue. The market capitalisation of Palatin Technologies is US$17.87 million. Palatin Technologies has a price to earnings ratio (PE ratio) of -0.62.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results

Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results PR Newswire CRANBURY, N.J., Nov. 14, 2024 Obesity programs:Core focus on obesity includes exploratory co-administration...

Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024

Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024 PR Newswire CRANBURY, N.J., Nov. 8, 2024 CRANBURY, N.J., Nov. 8, 2024...

Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024

Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024 PR Newswire CRANBURY, N.J., Nov. 4, 2024 Oral PL7737 significantly...

Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity

Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity PR Newswire CRANBURY, N.J., Oct...

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form EFFECT - Notice of Effectiveness

Inflammatory Disease Healing Data via Palatin's Novel Melanocortin Receptor Agonists Presented at the 19th Annual Peptide Therapeutics Symposium

Inflammatory Disease Healing Data via Palatin's Novel Melanocortin Receptor Agonists Presented at the 19th Annual Peptide Therapeutics Symposium PR Newswire CRANBURY, N.J., Oct. 24, 2024 Data...

Palatin Presents Foundational Data on Novel and Highly Selective Melanocortin 4 Receptor Agonists at the 19th Annual Peptide Therapeutics Symposium

Palatin Presents Foundational Data on Novel and Highly Selective Melanocortin 4 Receptor Agonists at the 19th Annual Peptide Therapeutics Symposium PR Newswire CRANBURY, N.J., Oct. 23, 2024 High...

기간	변동	변동 %	시가	고가	저가	평균 일일 거래량	VWAP
1	-0.15	-13.6363636364	1.1	1.1	0.9	230616	0.970768	CS
4	-0.15	-13.6363636364	1.1	1.4	0.9	266695	1.14950347	CS
12	-0.69	-42.0731707317	1.64	1.72	0.68	285123	1.06312516	CS
26	-1.12	-54.1062801932	2.07	2.13	0.68	194852	1.25767676	CS
52	-0.94	-49.7354497354	1.89	5.65	0.68	339877	2.28521439	CS
156	0.575	153.333333333	0.375	8.6	0.1811	1069098	0.8529184	CS
260	0.1594	20.1619023526	0.7906	8.6	0.1811	1573167	0.75479002	CS

가장 활성
% 상승자
% 패자

기호	가격	볼륨
BIGYYieldmax Target 12 Big 50 Option Income ETF	49.91 (175.90%)	13.02k
SNOYYieldmax Snow Option Income Strategy ETF	US$ 21.5899 (22.95%)	34.14k
HYLNHyliion Holdings Corp	US$ 3.4299 (17.87%)	1.17M
ETUT Rex 2X Long Ether Daily Target ETF	US$ 40.31 (14.13%)	31.3k
ETHU2x Ether ETF	US$ 8.4285 (14.05%)	25.2M
CATXPerspective Therapeutics Inc	US$ 3.3601 (-45.54%)	4.19M
ROLRHigh Roller Technologies Inc	US$ 6.14 (-15.31%)	16.29k
ETHDProshares Ultrashort Ether ETF	US$ 27.05 (-13.96%)	84.09k
CHROChannel Therapeutics Corporation	US$ 0.5353 (-13.55%)	39.38k
ETQT Rex 2X Inverse Ether Daily Target ETF	US$ 12.42 (-12.00%)	3.92k
MSTZT Rex 2X Inverse MSTR Daily Target ETF	US$ 0.8223 (1.17%)	771.58M
SOXLDirexion Daily Semiconductor Bull 3X Shares	US$ 27.6028 (1.74%)	47.64M
NVDQT Rex 2X Inverse NVIDIA Daily Target ETF	US$ 3.1301 (2.29%)	35.68M
SPXSDirexion Daily S&P 500 Bear 3X Shares New	US$ 6.145 (-0.57%)	30.07M
ETHU2x Ether ETF	US$ 8.4285 (14.05%)	25.2M